Regular Article
Diagnosis and treatment of hepatic encephalopathy

https://doi.org/10.1053/bega.2000.0141Get rights and content

Abstract

Hepatic encephalopathy arises from the combination of hepatocellular dysfunction and portal-systemic shunting. Encephalopathy is more prominent in advanced stages of liver cirrhosis and signals the presence of fulminant hepatic failure in patients with acute liver injury. As important as the extent of shunting is the presence of large spontaneous collaterals. Ammonia continues to be a leading toxin influencing brain function. Endogenous benzodiazepines and cytokines may contribute to one of ammonia’s key effects in the brain: astrocyte swelling. The diagnosis of hepatic encephalopathy is a diagnosis of exclusion; the search for a precipitating factor should be started immediately in all cases of encephalopathy. The treatment of hepatic encephalopathy has three aims: decrease the nitrogenous load from the gut, improve the extra-intestinal elimination of ammonia and counteract central abnormalities of neurotransmission. The mainstay of treatment is directed at the colon. Newer approaches targeting the brain, such as flumazenil, have become available.

References (82)

  • HO Conn et al.

    Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial

    Gastroenterology

    (1977)
  • M Plauth et al.

    ESPEN guidelines for nutrition in liver disease and transplantation

    Clinical Nutrition

    (1997)
  • RF Butterworth

    Complications of cirrhosis III. Hepatic encephalopathy

    Journal of Hepatology

    (2000)
  • F Simmons et al.

    A controlled clinical trial of lactulose in hepatic encephalopathy

    Gastroenterology

    (1970)
  • M Uribe et al.

    Lactose enemas plus placebo tablets vs. neomycin tablets plus starch enemas in acute portal systemic encephalopathy. A double-blind randomized controlled study

    Gastroenterology

    (1981)
  • P Reding et al.

    Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial

    Lancet

    (1984)
  • G Marchesini et al.

    Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis

    Hepatology

    (1996)
  • S Stauch et al.

    Oral L -ornithine- L -aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study

    Journal of Hepatology

    (1998)
  • JH James et al.

    Hyperammonaemia, plasma aminoacid imbalance, and blood-brain aminoacid transport: a unified theory of portal-systemic encephalopathy

    Lancet

    (1979)
  • MY Morgan

    Branched chain amino acids in the management of chronic liver disease. Facts and fantasies

    Journal of Hepatology

    (1990)
  • CD Naylor et al.

    Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis

    Gastroenterology

    (1989)
  • M Plauth et al.

    Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-controlled crossover study

    Journal of Hepatology

    (1993)
  • MY Morgan et al.

    Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy

    Gastroenterology

    (1980)
  • J Bernuau et al.

    Fulminant and subfulminant liver failure: definitions and causes

    Seminars in Liver Disease

    (1986)
  • JG O’Grady et al.

    Acute liver failure: redefining the syndromes

    Lancet

    (1993)
  • AT Blei

    Brain edema and portal-systemic encephalopathy

    Liver Transplantation

    (2000)
  • J Canalese et al.

    Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure

    Gut

    (1982)
  • M Groeneweg et al.

    Subclinical hepatic encephalopathy impairs daily functioning

    Hepatology

    (1998)
  • J Cordoba et al.

    High prevalence of sleep disturbance in cirrhosis

    Hepatology

    (1998)
  • AS Hazell et al.

    Hepatic encephalopathy: an update of pathophysiologic mechanisms

    Proceedings of the Society for Experimental Biology and Medicine

    (1999)
  • JO Clemmesen et al.

    Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration

    Hepatology

    (1999)
  • AH Lockwood et al.

    Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy

    Journal of Cerebral Blood Flow and Metabolism

    (1991)
  • E Lugaresi et al.

    Endozepine stupor. Recurring stupor linked to endozepine-4 accumulation

    Brain

    (1998)
  • G Barbaro et al.

    Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study

    Hepatology

    (1998)
  • EA Jones et al.

    Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure?

    Metabolic Brain Disease

    (1998)
  • M Fujimoto et al.

    Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance

    Alcohol Clinical and Experimental Results

    (2000)
  • J Licinio et al.

    Pathways and mechanisms for cytokine signaling of the central nervous system

    Journal of Clinical Investigation

    (1997)
  • PG Traber et al.

    Electron microscopic evaluation of brain edema in rabbits with galactosamine-induced fulminant hepatic failure: ultrastructure and integrity of the blood-brain barrier

    Hepatology

    (1987)
  • M Kato et al.

    Electron microscopic study of brain capillaries in cerebral edema from fulminant hepatic failure

    Hepatology

    (1992)
  • D Hunssinger et al.

    Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema

    Journal of Hepatology

    (2000)
  • Cited by (0)

    f1

    Address for correspondence: Northwestern Faculty Foundation, 675 N St. Clair—Suite 15-250, Chicago, IL 60611, USA.

    View full text